<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928771</url>
  </required_header>
  <id_info>
    <org_study_id>D3250C00017</org_study_id>
    <nct_id>NCT01928771</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma</brief_title>
  <official_title>A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting Î²2 Agonist in Patients With Uncontrolled Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Benralizumab reduces the number of asthma
      exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 19, 2013</start_date>
  <completion_date type="Actual">April 5, 2016</completion_date>
  <primary_completion_date type="Actual">April 5, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils &gt;=300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils &lt; 300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>The annual exacerbation rate associated with an emergency room visit or a hospitalization (adjudicated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With &gt;=1 Asthma Exacerbations</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Asthma Exacerbation</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils &gt;=300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils &lt;300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils &gt;=300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils &lt;300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Asthma Rescue Medication</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>Change from baseline to week 48 in number of rescue medication use (puffs/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Home Lung Function Assessment Based on Morning PEF</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>Change from baseline to week 48 in home lung function morning peak expiratory flow [PEF]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Home Lung Function Assessment Based on Evening PEF</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>Change from baseline to week 48 in home lung function evening peak expiratory flow [PEF]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Night Awakening Due to Asthma</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>Change from baseline to Week 48 on proportion of night awakening due to asthma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils &gt;=300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils &lt;300/uL</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Benralizumab</measure>
    <time_frame>Baseline, week 4, week 4 day 6, week 8, week 16, week 24, week 32, week 40, week 48, week 56</time_frame>
    <description>Mean PK concentrations at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of Benralizumab</measure>
    <time_frame>Pre-treatment until end of follow-up</time_frame>
    <description>Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at &gt;=2 post baseline assessments (with &gt;=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extend of Exposure</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>Extend of exposure is defined as duration of treatment in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 48 in AQLQ(S)+12</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of &gt;=0.5 are considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 48 in EQ-5D-5L VAS</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Work Productivity Loss Due to Asthma</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. The work productivity loss is only applicable to patients who employed, which is only subset of the study population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Productivity Loss Due to Asthma in Classroom</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
    <description>WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable to patients who attending classes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Utilized Health Care Resources</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and Clinician's Responder Assessment to Treatment</measure>
    <time_frame>Immediately following the first administration of study drug through Study Week 48</time_frame>
    <description>CGIC (Clinical global impression of change), and PGIC (Patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse). This is additional measures collected after second Amendment, thus not all patients had data to be analyzed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2681</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Benralizumab 30 mg q.4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benralizumab 30 mg q.8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously every 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab</intervention_name>
    <description>Benralizumab subcutaneously on study week 0 until study week 44 inclusive.</description>
    <arm_group_label>Benralizumab 30 mg q.4 weeks</arm_group_label>
    <arm_group_label>Benralizumab 30 mg q.8 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneously on study week 0 until study week 44 inclusive.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent for study participation must be obtained prior to any study
             related procedures being performed (local regulations are to be followed in
             determining the assent/consent requirements for children and parent[s]/guardian[s])
             and according to international guidelines and/or applicable European Union guidelines.

          2. Female and Male aged 12 to 75 years inclusively, at the time of visit 1. For those
             patients, who are 17 on the day of Visit 1 but will turn 18 after this day, will be
             considered an adolescent for the purposes of this trial.

          3. History of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS
             (&gt;250Î¼g fluticasone dry powder formulation equivalents total daily dose) and a LABA,
             for at least 12 months prior to Visit 1

          4. Documented treatment with ICS and LABA for at least 3 months prior to Visit 1 with or
             without oral corticosteroids and additional asthma controllers.

               -  For subjects 18 years of age and older, the ICS dose must be &gt;500 mcg/day
                  fluticasone propionate dry powder formulation or equivalent daily.

               -  For subjects ages 12-17, the ICS dose must be â¥500 mcg /day fluticasone
                  propionate dry powder formulation or equivalent daily.

        Exclusion criteria:

          1. Clinically important pulmonary disease other than asthma (e.g. active lung infection,
             COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome
             associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary
             ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other
             than asthma, that are associated with elevated peripheral eosinophil counts (e.g.
             allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome,
             hypereosinophilic syndrome)

          2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal,
             hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic,
             haematological, psychiatric, or major physical impairment that is not stable in the
             opinion of the Investigator and could:

               -  Affect the safety of the patient throughout the study

               -  Influence the findings of the studies or their interpretations

               -  Impede the patient's ability to complete the entire duration of study

          3. Acute upper or lower respiratory infections requiring antibiotics or antiviral
             medication within 30 days prior to the date informed consent is obtained or during the
             screening/run-in period

          4. Any clinically significant abnormal findings in physical examination, vital signs,
             haematology, clinical chemistry, or urinalysis during screening/run-in period, which
             in the opinion of the Investigator, may put the patient at risk because of his/her
             participation in the study, or may influence the results of the study, or the
             patient's ability to complete entire duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene R. Bleecker, MD, Professor of Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Genomics and Personalized Medicine Research, Medical Center Boulevard, Winston-Salem, North Carolina 27157</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Foley</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsboro</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cutler Bay</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackonsville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lynn Haven</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sebring</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Mitchell</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Opelousas</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gardner</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sparks</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northfield</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Union</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hopewell Jct</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oregon</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Feasterville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenixville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hodges</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mt Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Allen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dickinson</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncanville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pharr</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sealy</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Splendora</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hopewell</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Box Hill</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clayton</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Concord</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Lambton Heights</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prahran</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Randwick</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woolloongabba</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo AndrÃ©</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sorocaba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>SÃ£o Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dupnitsa</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pernik</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samokov</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sliven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Velingrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yambol</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlovy Vary</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rokycany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strakonice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teplice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le Kremlin BicÃªtre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le Mans Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon Cedex 4</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pau Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pringy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Pierre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Legnago</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Pietro Vernotico</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucheon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jeju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morelia</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cusco</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Surco</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>BiaÅystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dobre Miasto</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>GdaÅsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>GiÅ¼ycko</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>KoÅcian</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Legnica</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>PoznaÅ</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Proszowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>RzeszÃ³w</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sosnowiec</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>WoÅomin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>WrocÅaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zgierz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>ÅÃ³dÅº</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izhevsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint - Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>StPetersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladikavkaz</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladimir</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Benoni</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mowbray</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stanger</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>MÃ¡laga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sagunto(Valencia)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bradford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chertsey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chippenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Darlington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>High Heaton/Newcastle upon Tyn</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Soham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Somerset</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stevenage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1845&amp;filename=D3250C00017_Revised_CSP_SIROCCO.pdf</url>
    <description>D3250C00017CSP3redacted</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2013</study_first_submitted>
  <study_first_submitted_qc>August 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2013</study_first_posted>
  <results_first_submitted>September 28, 2016</results_first_submitted>
  <results_first_submitted_qc>March 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 3, 2017</results_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma,</keyword>
  <keyword>Bronchial Diseases,</keyword>
  <keyword>Respiratory Tract Diseases,</keyword>
  <keyword>Lung Diseases,</keyword>
  <keyword>Obstructive Lung Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>2681 participants signed informed consent form, 2232 participants entered screening/run-in period,1205 participants were randomised to receive treatment with benralizumab 30 mg Q4W, Q8W, or placebo. Of the 1205 patients randomised, 1204 patients received treatment with the study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Benralizumab 30 mg q.4 Weeks</title>
          <description>Benralizumab administered every 4 weeks subcutaneously.</description>
        </group>
        <group group_id="P2">
          <title>Benralizumab 30 mg q.8 Weeks</title>
          <description>Benralizumab administered every 8 weeks subcutaneously.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="400"/>
                <participants group_id="P2" count="398"/>
                <participants group_id="P3" count="407"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="399"/>
                <participants group_id="P2" count="398"/>
                <participants group_id="P3" count="407"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="354"/>
                <participants group_id="P2" count="358"/>
                <participants group_id="P3" count="367"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study-Specific Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe Non-Compliance to Protocol</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Benralizumab 30 mg q.4 Weeks</title>
          <description>Benralizumab administered every 4 weeks subcutaneously.</description>
        </group>
        <group group_id="B2">
          <title>Benralizumab 30 mg q.8 Weeks</title>
          <description>Benralizumab administered every 8 weeks subcutaneously.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="399"/>
            <count group_id="B2" value="398"/>
            <count group_id="B3" value="407"/>
            <count group_id="B4" value="1204"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" spread="13.4"/>
                    <measurement group_id="B2" value="47.6" spread="14.5"/>
                    <measurement group_id="B3" value="48.7" spread="14.9"/>
                    <measurement group_id="B4" value="48.8" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="269"/>
                    <measurement group_id="B4" value="796"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils &gt;=300/uL</title>
        <description>The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils &gt;=300/uL</title>
          <description>The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
          <units>events/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.60" upper_limit="0.89"/>
                    <measurement group_id="O2" value="0.65" lower_limit="0.53" upper_limit="0.80"/>
                    <measurement group_id="O3" value="1.33" lower_limit="1.12" upper_limit="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils &lt; 300/uL</title>
        <description>The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &lt;300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils &lt; 300/uL</title>
          <description>The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF</description>
          <population>Full analysis set, Baseline eosinophils &lt;300/uL</population>
          <units>events/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.65" upper_limit="1.11"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.78" upper_limit="1.28"/>
                    <measurement group_id="O3" value="1.21" lower_limit="0.96" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.268</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations</title>
        <description>The annual exacerbation rate associated with an emergency room visit or a hospitalization (adjudicated)</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations</title>
          <description>The annual exacerbation rate associated with an emergency room visit or a hospitalization (adjudicated)</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
          <units>events/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.07" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.04" upper_limit="0.11"/>
                    <measurement group_id="O3" value="0.18" lower_limit="0.13" upper_limit="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes covariates treatment group, region, number of exacerbations resulting in ER/hospitalization in the previous year, and use of OCS</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes covariates treatment group, region, number of exacerbations resulting in ER/hospitalization in the previous year, and use of OCS</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With &gt;=1 Asthma Exacerbations</title>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With &gt;=1 Asthma Exacerbations</title>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="84.227"/>
                    <measurement group_id="O2" value="93" spread="72.002"/>
                    <measurement group_id="O3" value="135" spread="74.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Proportion of patients with &gt;=1 asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region, number of exacerbations in the previous year, use of OCS</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Proportion of patients with &gt;=1 asthma exacerbation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region, number of exacerbations from the previous year, use of OCS</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Asthma Exacerbation</title>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Asthma Exacerbation</title>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="84.227">Median time is not estimable due to less than 50% patients had exacerbations occurred.</measurement>
                    <measurement group_id="O2" value="NA" spread="72.002">Median time is not estimable due to less than 50% patients had exacerbations occurred.</measurement>
                    <measurement group_id="O3" value="300" spread="74.434" lower_limit="199">Upper 95% CI for median is not estimable due to the curve representing the upper confidence limit of the survival function is above 50%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time to first exacerbation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model includes treatment, number of exacerbations in the previous year, region, use of OCS</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time to first exacerbation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Model includes treatment, number of exacerbations from the previous year, region, use of OCS</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils &gt;=300/uL</title>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinopiles &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils &gt;=300/uL</title>
          <population>Full analysis set, Baseline eosinopiles &gt;=300/uL</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="235"/>
                <count group_id="O3" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.353" spread="0.503"/>
                    <measurement group_id="O2" value="0.398" spread="0.546"/>
                    <measurement group_id="O3" value="0.237" spread="0.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit and treatment by visit</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.106</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.196</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit and treatment by visit</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.159</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.068</ci_lower_limit>
            <ci_upper_limit>0.249</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils &lt;300/uL</title>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinopiles &lt;300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils &lt;300/uL</title>
          <population>Full analysis set, Baseline eosinopiles &lt;300/uL</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.115" spread="0.417"/>
                    <measurement group_id="O2" value="0.238" spread="0.483"/>
                    <measurement group_id="O3" value="0.140" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.644</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit and treatment by visit</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.134</ci_lower_limit>
            <ci_upper_limit>0.083</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit and treatment by visit</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.102</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>0.208</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils &gt;=300/uL</title>
        <description>Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils &gt;=300/uL</title>
          <description>Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="1.31"/>
                    <measurement group_id="O2" value="-1.34" spread="1.27"/>
                    <measurement group_id="O3" value="-1.03" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.442</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline asthma symptom score, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline asthma symptom score, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils &lt;300/uL</title>
        <description>Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &lt;300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils &lt;300/uL</title>
          <description>Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
          <population>Full analysis set, Baseline eosinophils &lt;300/uL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="1.19"/>
                    <measurement group_id="O2" value="-1.04" spread="1.24"/>
                    <measurement group_id="O3" value="-0.78" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.169</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline asthma symptom score, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline asthma symptom score, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Asthma Rescue Medication</title>
        <description>Change from baseline to week 48 in number of rescue medication use (puffs/day)</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Asthma Rescue Medication</title>
          <description>Change from baseline to week 48 in number of rescue medication use (puffs/day)</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
          <units>Puffs/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.74" spread="4.29"/>
                    <measurement group_id="O2" value="-2.78" spread="3.90"/>
                    <measurement group_id="O3" value="-2.18" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline asthma medication use, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.081</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline asthma medication use, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Home Lung Function Assessment Based on Morning PEF</title>
        <description>Change from baseline to week 48 in home lung function morning peak expiratory flow [PEF]</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Home Lung Function Assessment Based on Morning PEF</title>
          <description>Change from baseline to week 48 in home lung function morning peak expiratory flow [PEF]</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.857" spread="84.227"/>
                    <measurement group_id="O2" value="36.994" spread="72.002"/>
                    <measurement group_id="O3" value="22.059" spread="74.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning PEF change from baseline to Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline morning PEF, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.20</ci_lower_limit>
            <ci_upper_limit>37.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning PEF change from baseline to Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline morning PEF, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>16.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.08</ci_lower_limit>
            <ci_upper_limit>30.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Home Lung Function Assessment Based on Evening PEF</title>
        <description>Change from baseline to week 48 in home lung function evening peak expiratory flow [PEF]</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Home Lung Function Assessment Based on Evening PEF</title>
          <description>Change from baseline to week 48 in home lung function evening peak expiratory flow [PEF]</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.806" spread="86.271"/>
                    <measurement group_id="O2" value="33.460" spread="74.017"/>
                    <measurement group_id="O3" value="14.784" spread="68.799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening PEF change from baseline to Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline evening PEF, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>21.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.86</ci_lower_limit>
            <ci_upper_limit>35.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening PEF change from baseline to Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline evening PEF, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>19.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.09</ci_lower_limit>
            <ci_upper_limit>33.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Night Awakening Due to Asthma</title>
        <description>Change from baseline to Week 48 on proportion of night awakening due to asthma</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Night Awakening Due to Asthma</title>
          <description>Change from baseline to Week 48 on proportion of night awakening due to asthma</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
          <units>Proportion of nights</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.314" spread="0.366"/>
                    <measurement group_id="O2" value="-0.380" spread="0.385"/>
                    <measurement group_id="O3" value="-0.26" spread="0.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.964</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline proportion of nights with nocturnal awakenings, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline proportion of nights with nocturnal awakenings, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils &gt;=300/uL</title>
        <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils &gt;=300/uL</title>
          <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="1.18"/>
                    <measurement group_id="O2" value="-1.47" spread="1.05"/>
                    <measurement group_id="O3" value="-1.12" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils &lt;300/uL</title>
        <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &lt;300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils &lt;300/uL</title>
          <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
          <population>Full analysis set, Baseline eosinophils &lt;300/uL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="1.07"/>
                    <measurement group_id="O2" value="-1.14" spread="1.11"/>
                    <measurement group_id="O3" value="-0.89" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.107</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Benralizumab</title>
        <description>Mean PK concentrations at each visit</description>
        <time_frame>Baseline, week 4, week 4 day 6, week 8, week 16, week 24, week 32, week 40, week 48, week 56</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Benralizumab</title>
          <description>Mean PK concentrations at each visit</description>
          <population>PK analysis set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="391"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=395, 386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Value is less than lower limit of quantification</measurement>
                    <measurement group_id="O2" value="NA">Value is less than lower limit of quantification</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=393, 375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632.84" spread="152.14"/>
                    <measurement group_id="O2" value="629.89" spread="169.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 day 6 (n=54, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1368.98" spread="633.33"/>
                    <measurement group_id="O2" value="1273.7" spread="688.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=377, 366)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="916.25" spread="142.53"/>
                    <measurement group_id="O2" value="881.57" spread="156.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=358, 350)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1024.26" spread="174.08"/>
                    <measurement group_id="O2" value="250.84" spread="228.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=349, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="926.62" spread="231.75"/>
                    <measurement group_id="O2" value="184.08" spread="298.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=260, 267)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="853.67" spread="248.6"/>
                    <measurement group_id="O2" value="152.73" spread="394.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=328, 333)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="967.15" spread="218.32"/>
                    <measurement group_id="O2" value="157.22" spread="364.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=333, 333)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="864.37" spread="283.87"/>
                    <measurement group_id="O2" value="162.51" spread="352.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (n=63, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="833.91"/>
                    <measurement group_id="O2" value="6.66" spread="321.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of Benralizumab</title>
        <description>Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at &gt;=2 post baseline assessments (with &gt;=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive.</description>
        <time_frame>Pre-treatment until end of follow-up</time_frame>
        <population>Safety analysis set, note that 4 patients who were randomized to q.8 regimen treated with q.4 regimen. Thus 403 patients treated with q.4 rather than 399, 394 patients treated with q.8 rather than 398. However, data were only available for 402 patients in q.4, and 393 patients in q.8.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of Benralizumab</title>
          <description>Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at &gt;=2 post baseline assessments (with &gt;=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive.</description>
          <population>Safety analysis set, note that 4 patients who were randomized to q.8 regimen treated with q.4 regimen. Thus 403 patients treated with q.4 rather than 399, 394 patients treated with q.8 rather than 398. However, data were only available for 402 patients in q.4, and 393 patients in q.8.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive at any visit (n=402, 393, 407)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Base- and post baseline positive (n=393, 381, 396)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only post baseline positive (n=396, 389, 402)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistently positive (n=396, 389, 402)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transiently positive (n=396, 389, 402)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only baseline positive (n=399, 385, 401)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extend of Exposure</title>
        <description>Extend of exposure is defined as duration of treatment in days</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Safety analysis set, note that 4 patients who were randomized to q.8 regimen treated with q.4 regimen. Thus 403 patients treated with q.4 rather than 399, 394 patients treated with q.8 rather than 398.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Extend of Exposure</title>
          <description>Extend of exposure is defined as duration of treatment in days</description>
          <population>Safety analysis set, note that 4 patients who were randomized to q.8 regimen treated with q.4 regimen. Thus 403 patients treated with q.4 rather than 399, 394 patients treated with q.8 rather than 398.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="394"/>
                <count group_id="O3" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285.86" spread="67.446"/>
                    <measurement group_id="O2" value="288.02" spread="66.683"/>
                    <measurement group_id="O3" value="289.38" spread="61.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 48 in AQLQ(S)+12</title>
        <description>AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of &gt;=0.5 are considered clinically meaningful.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 48 in AQLQ(S)+12</title>
          <description>AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of &gt;=0.5 are considered clinically meaningful.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="1.18"/>
                    <measurement group_id="O2" value="1.56" spread="1.17"/>
                    <measurement group_id="O3" value="1.25" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.081</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes covariates treatment, baseline AQLQ(S)+12 score, region, use of OCS, visit, and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes covariates treatment, baseline AQLQ(S)+12 score, region, use of OCS, visit, and visit by treatment</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 48 in EQ-5D-5L VAS</title>
        <description>EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 48 in EQ-5D-5L VAS</title>
          <description>EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="186"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="21.82"/>
                    <measurement group_id="O2" value="16.5" spread="23.66"/>
                    <measurement group_id="O3" value="12.5" spread="21.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Work Productivity Loss Due to Asthma</title>
        <description>WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. The work productivity loss is only applicable to patients who employed, which is only subset of the study population.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL for patients who employed</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Work Productivity Loss Due to Asthma</title>
          <description>WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. The work productivity loss is only applicable to patients who employed, which is only subset of the study population.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL for patients who employed</population>
          <units>Percent of productivity loss</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.31" spread="24.169"/>
                    <measurement group_id="O2" value="26.11" spread="23.06"/>
                    <measurement group_id="O3" value="35.36" spread="24.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Productivity Loss Due to Asthma in Classroom</title>
        <description>WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable to patients who attending classes</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL who attending classes</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Productivity Loss Due to Asthma in Classroom</title>
          <description>WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable to patients who attending classes</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL who attending classes</population>
          <units>Percent of productivity loss</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.97" spread="25.311"/>
                    <measurement group_id="O2" value="27.17" spread="38.456"/>
                    <measurement group_id="O3" value="49.1" spread="25.801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Utilized Health Care Resources</title>
        <time_frame>Immediately following the first administration of study drug through Study Week 48.</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300=/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Utilized Health Care Resources</title>
          <population>Full analysis set, Baseline eosinophils &gt;=300=/uL</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency department visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled outpatient visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Home visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telephone calls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ambulance transports</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient and Clinician's Responder Assessment to Treatment</title>
        <description>CGIC (Clinical global impression of change), and PGIC (Patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse). This is additional measures collected after second Amendment, thus not all patients had data to be analyzed.</description>
        <time_frame>Immediately following the first administration of study drug through Study Week 48</time_frame>
        <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered every 4 weeks subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered every 8 weeks subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Patient and Clinician's Responder Assessment to Treatment</title>
          <description>CGIC (Clinical global impression of change), and PGIC (Patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse). This is additional measures collected after second Amendment, thus not all patients had data to be analyzed.</description>
          <population>Full analysis set, Baseline eosinophils &gt;=300/uL</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CGIC improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CGIC much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CGIC very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CGIC total responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGIC improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGIC much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGIC very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGIC total responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>There were 400 patients randomized to Benra q.4, and 398 patients randomized to Benra q.8. One patient in Benra q.4 was never treated. In addition, 4 patients who were randomized to q.8 group, but were treated with q.4 schedule. So 403 patients were treated with q.4 regimen, and 394 patients were treated with q.8 regimen.</desc>
      <group_list>
        <group group_id="E1">
          <title>Benralizumab 30 mg q.4 Weeks</title>
          <description>Benralizumab administered every 4 weeks subcutaneously.</description>
        </group>
        <group group_id="E2">
          <title>Benralizumab 30 mg q.8 Weeks</title>
          <description>Benralizumab administered every 8 weeks subcutaneously.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="394"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Optic nerve disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic granulomatous angiitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Bullous impetigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenolymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Cerebral venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="29" subjects_affected="23" subjects_at_risk="403"/>
                <counts group_id="E2" events="33" subjects_affected="24" subjects_at_risk="394"/>
                <counts group_id="E3" events="42" subjects_affected="32" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Urticaria papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="394"/>
                <counts group_id="E3" subjects_affected="219" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="403"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="394"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="403"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="394"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="403"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="394"/>
                <counts group_id="E3" events="15" subjects_affected="11" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="403"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="394"/>
                <counts group_id="E3" events="41" subjects_affected="30" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="403"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="394"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="403"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="394"/>
                <counts group_id="E3" events="31" subjects_affected="23" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="62" subjects_affected="47" subjects_at_risk="403"/>
                <counts group_id="E2" events="69" subjects_affected="47" subjects_at_risk="394"/>
                <counts group_id="E3" events="64" subjects_affected="49" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="403"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="394"/>
                <counts group_id="E3" events="20" subjects_affected="14" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="403"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="394"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="403"/>
                <counts group_id="E2" events="34" subjects_affected="22" subjects_at_risk="394"/>
                <counts group_id="E3" events="43" subjects_affected="29" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="74" subjects_affected="45" subjects_at_risk="403"/>
                <counts group_id="E2" events="51" subjects_affected="32" subjects_at_risk="394"/>
                <counts group_id="E3" events="73" subjects_affected="37" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="403"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="394"/>
                <counts group_id="E3" events="19" subjects_affected="12" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="403"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="394"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="403"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="394"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="38" subjects_affected="31" subjects_at_risk="403"/>
                <counts group_id="E2" events="61" subjects_affected="37" subjects_at_risk="394"/>
                <counts group_id="E3" events="28" subjects_affected="21" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="64" subjects_affected="48" subjects_at_risk="403"/>
                <counts group_id="E2" events="38" subjects_affected="27" subjects_at_risk="394"/>
                <counts group_id="E3" events="102" subjects_affected="60" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="403"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="394"/>
                <counts group_id="E3" events="15" subjects_affected="11" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="403"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="394"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>â¥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZâs Confidential Information without AZâs written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mitchell Goldman , Medical Science Director</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+1 301 398 0323</phone>
      <email>Mitchell.Goldman@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

